+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Safety and efficacy of rabeprazole in combination with four antibiotic regimens for the eradication of Helicobacter pylori in patients with chronic gastritis with or without peptic ulceration



Safety and efficacy of rabeprazole in combination with four antibiotic regimens for the eradication of Helicobacter pylori in patients with chronic gastritis with or without peptic ulceration



American Journal of Gastroenterology 93(10): 1909-1913



Rabeprazole is a new fast acting proton pump inhibitor that has recently been proven to be effective in the treatment of peptic ulceration and reflux esophagitis. The aim of this study was to evaluate rabeprazole in combination with antibiotics for the eradication of Helicobacter pylori (H. pylori) in patients with chronic active gastritis with or without peptic ulcer disease. Seventy-five H. pylori-infected patients were randomized in a double-blind fashion to receive a 7-day treatment regimen consisting of: RAC, RAM, RCM, or RC (R=rabeprazole 20 mg b.d., A=amoxycillin 1 g b.d., C=clarithromycin 500 mg b.d., M=metronidazole 400 mg b.d.). Randomized patients were H. pylori-positive by gastric biopsy urease test, histology and 13C urea breath test (13C-UBT). H. pylori eradication was assessed by 13C-UBT, 4 and 8 wk after finishing treatment. Endoscopy with histology and culture for antibiotic sensitivity testing was performed pretreatment and if treatment failed. On an intention-to-treat analysis, treatment success was: RCM 100%, RAC 95%, RAM 90%, and RC 63%. The most common side effects were loose stools, headache, and taste disturbance, but there were no serious adverse events related to the study medication. The two patients failing RAM treatment had metronidazole-resistant strains before and after treatment. None of the pretreatment H. pylori isolates from six patients failing RC were clarithromycin resistant, but three of five successfully cultured posttreatment had developed clarithromycin resistance. Rabeprazole-based triple therapy with two antibiotics for 1 wk is safe and effective in eradicating H. pylori. Dual therapy with clarithromycin is less successful, and the majority of treatment failures develop clarithromycin resistance.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 047301480

Download citation: RISBibTeXText

PMID: 9772054

DOI: 10.1111/j.1572-0241.1998.00582.x


Related references

Safety and efficacy of 7-day rabeprazole- and omeprazole-based triple therapy regimens for the eradication of Helicobacter pylori in patients with documented peptic ulcer disease. Alimentary Pharmacology and Therapeutics 17(8): 1065-1074, 15 April, 2003

Efficacy of different antibiotic regimens for eradication treatment of Helicobacter pylori infection in peptic ulcer disease in Tanzanian patients. Tropical Doctor 33(4): 225-228, 2003

A multicenter study to compare the efficacy and safety of 3 7 day rabeprazole based triple therapy regimens for helicobacter pylori eradication. Digestive Disease Week Abstracts and Itinerary Planner: Abstract No. M1494, 2003

Efficacy of esomeprazole and rabeprazole for Helicobacter pylori eradication in patients with peptic ulcer. Helicobacter 8(4): 469, 2003

Eradication of Helicobacter pylori in management of peptic ulceration. Evidence supports eradication only in patients who have helicobacter and peptic ulceration. Bmj 310(6978): 531, 1995

Cytotoxin production and neutrophil activation by Helicobacter pylori in patients with peptic ulceration and chronic gastritis. Gut 37(Suppl. 1): A3, 1995

Comparison of H2-receptor antagonist- and proton-pump inhibitor-based triple regimens for the eradication of Helicobacter pylori in Chinese patients with gastritis or peptic ulcer. Journal of International Medical Research 31(6): 469-474, 2003

Helicobacter pylori associated chronic gastritis and peptic ulceration in patients taking non-steroidal anti-inflammatory drugs. Alimentary Pharmacology and Therapeutics 4(5): 515-522, 1990

Cytotoxin production and neutrophil activation by strains of Helicobacter pylori isolated from patients with peptic ulceration and chronic gastritis. Gut 40(3): 431, 1997

A study on the efficacy of three-day versus seven-day rabeprazole-based triple therapy in the eradication of Helicobacter pylori in peptic ulcers. Gut 51(Suppl. 2): A61-A62, 2002

Association of cytotoxin production and neutrophil activation by strains of Helicobacter pylori isolated from patients with peptic ulceration and chronic gastritis. Gut 38(6): 841-845, 1996

Efficacy and safety of a ten-day Helicobacter pylori eradication regimen with rabeprazole, amoxicillin and clarithromycin. American Journal of Gastroenterology 98(9 Suppl.): S39, 2003

Efficacy and safety of rabeprazole, amoxicillin, and gatifloxacin after treatment failure of initial Helicobacter pylori eradication. Helicobacter 11(4): 231-236, 2006

Chemical gastritis and Helicobacter pylori related gastritis in patients receiving non-steroidal anti-inflammatory drugs: comparison and correlation with peptic ulceration. Journal of Clinical Pathology 45(2): 135-139, 1992

Sufficient efficacy of 20mg rabeprazole in combination with two antibiotics on Helicobacter pylori eradication Dose comparative analysis. Gastroenterology 116(4 Part 2): A113, 1999